# US 11,440,937 B2 · Chromatography process for purification of insulin analogues > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,440,937 B2 - Document ID: US11440937B2 - Status: Granted - Kind: B2 - Application number: 17/266,666 - Filed: 2019-08-20 - Published: 2021-11-18 - Granted: 2022-09-13 - Earliest claimed: 2018-08-20 - Assignees: Biocon Biologics Limited - Applicants: Biocon Biologics Limited - Inventors: Ramprabu Nagarajan; Minal Hashim; Azimoddin Minyasab Shaikh; Sandhya Hedge; Partha Hazra - Web page: https://patentgrep.com/patent/US11440937B2 ## CPC - C07K 1/20: Partition-, reverse-phase or hydrophobic interaction chromatography - C07K 14/62: Insulins - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The present invention relates to a process for purification of non-glycosylated insulin analogues 5 from a mixture comprising glycosylated and non-glycosylated proteins by removal of glycosylated proteins. The removal is achieved by combination of two RP-HPLC steps. ## Claims ### Claim 1 A two step process for purification of non-glycosylated insulin analogue(s) from a complex mixture comprising both non-glycosylated, and glycosylated insulin analogue(s), wherein the said purification process comprises the steps: a1) performing RP-HPLC with the said complex mixture in the presence of an ion pairing agent in combination with acetonitrile as an organic modifier at acidic pH ranging from about 3.5 to about 3.9 to yield an a1 first mixture comprising partially purified non-glycosylated insulin analogue; and b1) performing RP-HPLC on the a1 first mixture in the presence of an ion pairing agent that is different from step a1 in combination with acetonitrile as the organic modifier at alkaline pH ranging from about 7.3 to about 8.7 to obtain at least 99.95% purified non-glycosylated insulin analogue, wherein the ion pairing agent is selected from the group consisting of octane sulphonic acid, sodium perchlorate and tetrabutyl ammonium bisulphate (TBAB); or; a2) performing RP-HPLC on said complex mixture in the presence of an ion pairing agent in combination with acetonitrile as-an organic modifier at alkaline pH ranging from about 7.3 to about 8.7 to yield an a2 first mixture comprising partially purified non-glycosylated insulin analogue; and b2) performing RP-HPLC with the a2 first mixture in the presence of an ion pairing agent that is different from step a2 in combination with acetonitrile as the organic modifier at acidic pH ranging from about 3.5 to about 3.9 to obtain at least 99.95% purified non-glycosylated insulin analogue, wherein the ion pairing agent is selected from the group consisting of octane sulphonic acid, sodium perchlorate and tetrabutyl ammonium bisulphate (TBAB). ### Claim 2 (depends on 1) The two step process as claimed in claim 1, wherein the insulin analogue is selected from the group consisting of insulin Glargine, and insulin Lispro. ### Claim 3 (depends on 1) The two step process as claimed in claim 1, wherein obtaining the a1 first mixture comprising partially purified non-glycosylated insulin analogue obtained by low pH-based RP-HPLC comprises the following steps: a) packing a RP-HPLC column with a silica-based resin; b) loading of the RP-HPLC column with the complex mixture at a capacity of 4-12 g/L; c) washing of column with an ion pairing agent in combination with acetonitrile, at acidic pH ranging from about 3.5 to about 3.9; and d) performing a linear gradient of 24% to 31% for eluting the a1 first mixture of partially purified non-glycosylated insulin analogue. ### Claim 4 (depends on 1) The two step process as claimed in claim 1, wherein the at least 99.95% purified non-glycosylated insulin analogue obtained by high pH-based RP-HPLC following the low pH based RP-HPLC step comprises the following steps: a) packing a RP-HPLC column with silica-based resin b) loading of the RP-HPLC column with the a1 first mixture at a capacity of 4-12 g/L; c) washing of column with an ion pairing agent in combination with acetonitrile at alkaline pH ranging from about 7.3 to about 8.7; and d) performing a linear gradient of 25% to 29% for eluting at least 99.95% purified non-glycosylated insulin analogue. ### Claim 5 (depends on 1) The two step process as claimed in claim 1, wherein obtaining the b1 first mixture comprising partially purified non-glycosylated insulin analogue is obtained by high pH-based RP-HPLC comprising the following steps: a) packing a RP-HPLC column with silica-based resin b) loading of the RP-HPLC column with the complex mixture at a capacity of 4-12 g/L; c) washing of the RP-HPLC column with an ion pairing agent in combination with acetonitrile at alkaline pH ranging from about 7.3 to about 8.7; and d) performing a linear gradient of 25% to 29% for eluting the b1 first mixture of partially purified non-glycosylated insulin analogue. ### Claim 6 (depends on 1) The two step process as claimed in claim 1, wherein the at least 99.95% purified insulin analogue is obtained by low pH-based RP-HPLC following the high pH based RP-HPLC step comprises the following steps: a) packing a RP-HPLC column with silica-based resin; b) loading of RP-HPLC column with b1 first mixture at a capacity of 4-12 g/L; c) washing of column with an ion pairing agent in combination with acetonitrile, at acidic pH ranging from about 3.5 to about 3.9; and d) performing a linear gradient of 24% to 31% for eluting at least 99.95% purified non-glycosylated insulin analogue. ### Claim 7 (depends on 1) The two step process as claimed in claim 1, wherein said ion pairing agent is sodium perchlorate when insulin analogue is insulin Glargine, and wherein said ion pairing agent is TBAB when insulin analogue is insulin Lispro. ### Claim 8 (depends on 1) The two step process as claimed in claim 1, wherein insulin analog is insulin Glargine comprising less than 0.05% glycosylated variants of insulin Glargine. ### Claim 9 (depends on 1) The two step process as claimed in claim 1, wherein insulin analog is insulin Lispro comprising less than 0.05% glycosylated variants of insulin Lispro. ### Claim 10 (depends on 1) Non-glycosylated insulin Glargine at least 99.95% free of glycosylated variants of insulin Glargine obtained according to claim 1. ### Claim 11 (depends on 1) Non-glycosylated insulin Lispro at least 99.95% free of glycosylated variants of insulin Lispro obtained according to claim 1. ### Claim 12 (depends on 3) The two step process as claimed in claim 3, wherein the insulin is glargine ion pairing agent is Octane Sulphonic Acid (OSA) and the silica-based resin is Kromasil C8-100A-13 pm. ### Claim 13 (depends on 4) The two step process as claimed in claim 4, wherein the insulin is glargine, the ion pairing agent is sodium perchlorate and the silica-based resin is Kromasil C8-100A-13 pm. ### Claim 14 (depends on 5) The two step process as claimed in claim 5, wherein the insulin is glargine, the ion pairing agent is sodium perchlorate, and the silica-based resin is Kromasil C8-100A-13 pm. ### Claim 15 (depends on 6) The two step process as claimed in claim 6, wherein the insulin is glargine, the ion pairing agent is Octane Sulphonic Acid (OSA) and the silica-based resin is Kromasil C8-100A-13 pm. ### Claim 16 (depends on 3) The two step process as claimed in claim 3, wherein the insulin is lispro, the ion pairing agent is Octane Sulphonic Acid (OSA) and the silica-based resin is Kromasil C8-100A-13 pm. ### Claim 17 (depends on 4) The two step process as claimed in claim 4, wherein the insulin is lispro, the ion pairing agent is TBAB and the silica-based resin is Kromasil C8-100A-13 pm. ### Claim 18 (depends on 5) The two step process as claimed in claim 5, wherein the insulin is lispro, the ion pairing agent is TBAB, and the silica-based resin is Kromasil C8-100A-13 pm. ### Claim 19 (depends on 6) The two step process as claimed in claim 6, wherein the insulin is lispro, the ion pairing agent is Octane Sulphonic Acid (OSA) and the silica-based resin is Kromasil C8-100A-13 pm. ### Claim 20 (depends on 1) The two step process as claimed in claim 1, wherein the purified non-glycosylated insulin analogue contains less than 0.05% of the glycosylated insulin analogue.